Financials data is unavailable for this security.
View more
Year on year Kilitch Drugs (India) Ltd grew revenues 10.58% from 1.40bn to 1.54bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 39.75% net income growth from 104.48m to 146.01m.
Gross margin | 36.87% |
---|---|
Net profit margin | 7.03% |
Operating margin | 10.73% |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Kilitch Drugs (India) Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 88.07m or 5.70% of revenues. In addition the company used 1.46m for operations while cash used for investing totalled 95.45m.
Cash flow per share | 8.76 |
---|---|
Price/Cash flow per share | 42.30 |
Book value per share | -- |
---|---|
Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
Current ratio | -- |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items increased 36.71%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years) | 28.57 |
---|---|
EPS (TTM) vs TTM 1 year ago | 4.43 |